CBCI

Colorado Blood Cancer Institute ~ Hematology, Stem Cell Transplant, Immune Therapies, and Clinical Research @CBCIDocs @SarahCannonDocs @PresStLukesDenv

[CBCI @ColoradoBlood]

Congrats!!!

[CBCI @ColoradoBlood]

TIGIT study is currently enrolling for #myeloma and #lymphoma patients @ColoradoBlood #CBCI #TCTM20

[Michael Tees MD, MPH @MikeTeesMD]

@simone_minnie describing TIGIT as an excellent target post autoHCT in #myeloma #TCTM20

[CBCI @ColoradoBlood]

There may be options after failure of CAR T-cell therapy. #CBCI is opening an anti CD20-CD3 therapy soon...stay tuned #lymphoma

[Rabi Hanna @RabiHannaMD]

Dr. Nash reviewed data for autologous transplant for multiple sclerosis and announced the exciting future phase 3 study (BEAT MS) which will not use CD34 Selection and it will be done in collbration with @BMTCTN

[CBCI @ColoradoBlood]

One of our @CBCIDocs, Dr Richard Nash, discussing the use of autologous HCT in the treatment of #MultipleSclerosis and other autoimmune diseases at #BMTTandem18

[CBCI @ColoradoBlood]

Caregiver support groups available @ColoradoBlood. A safe place for participants to discuss unique #BMT stressors https://t.co/HG7JI8iurB

[BMT InfoNet @BMTInfoNet]

#NIHBMTLateEffects Caregiver needs highlighted as major topic researchers should address.

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

Patients will tell other patients things they won't tell HCP or caregivers. #Mentoring is key. #NIHBMTLateEffects https://t.co/lnL00x2GcW

[CBCI @ColoradoBlood]

@CBCIDocs thank @ASH_hematology and all the amazing #lymphoma scientists for sharing novel research at #ASHMLB16. Great meeting!

[CBCI @ColoradoBlood]

More compelling pre-clinical data on the possible role of HDAC inhibition in #lymphoma #ASHMLB16

[CBCI @ColoradoBlood]

@CBCIDocs at @ASH_hematology #lymphoma biology conference in CBCI's beautiful backyard! #ASHMLB16 #keeprising

[Jeffrey Matous, MD @MileHighMyeloma]

ASCO. Meta analysis shows revlimid maint emac after asct improves Overall survival dramatically

[ASH @ASH_hematology]

Dasatinib + Low-Intensity Chemo Results in Long-Term Survival for Older Patients with Ph+ ALL https://t.co/eIzxFyUNqf via @ASHClinicalNews

[CBCI @ColoradoBlood]

LLS Rocky Mountain Blood Cancer Conference today! Snowstorms can't keep away all our amazing patients. Thank you @llsusa @ColoradoBlood

[ASH @ASH_hematology]

FDA Grants Midostaurin Breakthrough Designation for AML https://t.co/UF6fvf2wVM via @OncLive #ASH15

[Blood Cancer United @BloodCancerUtd]

Because of your support, these numbers continue to rise! #hodgkinlymphoma #SomedayisToday

[NMDP @nmdp_org]

Cord blood can be used to treat more than 80 diseases,including blood cancers like leukemia & lymphoma. Learn more: https://t.co/fl8dnVCNSA

[Jeff Szer @marrow]

Porter: Relapsed ALL a great target for CAR T-cells #BMTTandem16

[Krishna Komanduri, MD, FASTCT @drkomanduri]

More than 8600 patients enrolled in @BMTCTN trials in 11 years!#BMTTandem16 #bmtsm @CIBMTR

[NMDP @nmdp_org]

@CIBMTR encouraging to see outcomes improving for patients 70+years who've had an allogeneic transplant #BMTTandem16 https://t.co/CAodf65RQ1